Some people get very sick from COVID-19, while others don't get infected at all, even when exposed. It turns out some people have a 'glitch' in their immune system or antibodies that block their own defenses. This work identifies these specific biological markers to predict who is at risk and create tailored treatments.
Clinical variability in COVID-19 means some patients suffer lethal disease or Long-COVID while others are resistant, but current age and co-morbidity data cannot predict these outcomes. There is a lack of precise diagnostic tools to identify high-risk individuals before severe complications occur.
The project is developing ready-to-use diagnostic tests for auto-antibodies and identifying genetic markers for vaccine failure and severe disease susceptibility.
If you are an IVD manufacturer dealing with a lack of precise screening tools for severe COVID risk — this project developed ready-to-use diagnostic tests for auto-antibodies to type I IFNs that allow for large-scale detection of high-risk patients.
If you are a drug developer dealing with low efficacy in broad patient groups — this project identified that 4% of critical pneumonia patients have specific inborn errors of immunity, enabling the creation of personalized medicine approaches for this niche.
If you are a biotech company dealing with vaccine failure in certain populations — this project identifies the genetic and immunological determinants of vaccine failure to help refine vaccine formulations for specific risk groups.
Based on available project data, specific pricing or cost structures for the diagnostic tests are not provided.
The project objective specifically mentions the development of ready-to-use diagnostic tests for large-scale detection of auto-antibodies.
Based on available project data, there is no specific information regarding patents or licensing agreements.
The project uses a 'bed side to bench' and 'bench to bed side' approach to translate genetic and immunological discoveries into personalized medicine and diagnostic tests.
The project period runs from 2022-06-01 to 2026-05-31, suggesting that final results and validated tests will be available toward 2026.
The consortium is heavily research-driven, consisting of 22 partners across 13 countries. It is dominated by universities (10) and research institutes (8), with a low industry presence of only 2 companies (9% ratio). This indicates the project is primarily in the translational research phase, moving from academic discovery toward industrial application.
Contact Aarhus Universitet (DK) regarding the UNDINE project coordination.
Contact us to identify licensing opportunities for the type I IFN auto-antibody tests.
